Form 4 for ORGO Organogenesis Holdings Inc.
Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0001062993-25-003231 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-21 | 2025-02-19 | ORGO | Montecalvo Antonio S. | VP, Health Policy | A - Grant | $0.00 | +42.5K | 196.7K | +28% | $0 |
| D | 2025-02-21 | 2025-02-19 | ORGO | Montecalvo Antonio S. | VP, Health Policy | A - Grant | $0.00 | +44.0K | 44.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-02-19 | A | A | 42,493 | $0.00 | 196,680 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-19 | A | A | 43,956 | $0.00 | 43,956 | D | $3.53 · — to 2035-02-19 | 43,956 Class A Common Stock | (F2) The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. |